Get the Stockscreener App
9.455
1.12%
0.105
After Hours:
9.36
-0.095
-1.00%
Novavax Inc stock is traded at $9.455, with a volume of 4.20M.
It is up +1.12% in the last 24 hours and down -0.37% over the past month.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
See More
Previous Close:
$9.35
Open:
$9.335
24h Volume:
4.20M
Relative Volume:
0.90
Market Cap:
$1.55B
Revenue:
$596.34M
Net Income/Loss:
$-87.84M
P/E Ratio:
-15.82
EPS:
-0.5975
Net Cash Flow:
$-97.62M
1W Performance:
+0.37%
1M Performance:
-0.37%
6M Performance:
+24.08%
1Y Performance:
+43.04%
1-Day Range:
$8.885
$9.48
1-Week Range:
$8.885
$10.12
52-Week Range:
$6.20
$11.97
Novavax Inc Stock (NVAX) Company Profile
Name
Novavax Inc
Sector
Industry
Phone
240-268-2000
Address
21 FIRSTFIELD RD, GAITHERSBURG, MD
Compare NVAX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
9.455 | 1.54B | 596.34M | -87.84M | -97.62M | -0.5975 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.93 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.50 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-25 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-28-25 | Resumed | H.C. Wainwright | Buy |
| Aug-20-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-17-25 | Initiated | Citigroup | Sell |
| Feb-28-25 | Initiated | BTIG Research | Buy |
| Jul-30-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-10-24 | Upgrade | BofA Securities | Underperform → Neutral |
| May-10-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-09-23 | Upgrade | B. Riley Securities | Neutral → Buy |
| Apr-20-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Mar-01-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-09-23 | Reiterated | B. Riley Securities | Buy |
| Dec-30-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-02-22 | Initiated | Jefferies | Hold |
| Sep-22-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-20-22 | Initiated | BofA Securities | Underperform |
| Feb-23-22 | Reiterated | B. Riley Securities | Buy |
| Feb-22-22 | Resumed | Jefferies | Buy |
| Jan-21-22 | Initiated | Cowen | Outperform |
| May-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-14-20 | Initiated | Jefferies | Buy |
| Aug-06-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-20 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
| Jul-16-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-29-20 | Reiterated | B. Riley FBR | Buy |
| Jun-29-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-05-20 | Upgrade | JP Morgan | Underweight → Neutral |
| May-28-20 | Reiterated | B. Riley FBR | Buy |
| May-12-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-27-19 | Resumed | B. Riley FBR | Buy |
| Aug-14-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-28-19 | Downgrade | Piper Jaffray | Overweight → Underweight |
| Dec-18-18 | Initiated | Ladenburg Thalmann | Buy |
| Dec-11-18 | Initiated | Oppenheimer | Outperform |
| Nov-26-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-21-18 | Upgrade | JP Morgan | Underweight → Overweight |
| Mar-29-18 | Upgrade | Seaport Global Securities | Neutral → Buy |
View All
Novavax Inc Stock (NVAX) Latest News
AtaiBeckley Completes VLS-01 Dosing in Phase IIb Depression Study - TradingView
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance Singapore
Novavax Inc. stock underperforms Monday when compared to competitors - MarketWatch
Does Novavax’s (NVAX) Russell Exit Quietly Recast Its Partnership-Driven, Royalty-Focused Equity Story? - simplywall.st
Novavax (NVAX) Stock Moves 1.36%: What You Should Know - Yahoo Finance
Novavax Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
(NVAX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
NVAX Stock Rises Overnight Ahead Of Q4 Print With Pfizer Tailwinds — Analyst Warns Of 20% Crash - Stocktwits
INO, MRNA, NVAX, EBS Jump Overnight: Trump Promises Full Hantavirus Report As Deadly Outbreak Sparks Vaccine Rally - Stocktwits
Novavax Stock Hits Over 1-Year High: Is Sanofi’s Flu-COVID Shot The Post-Pandemic Growth Driver? - Stocktwits
Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch
Novavax, Inc.(NasdaqGS:NVAX) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
Novavax, Inc.(NasdaqGS: NVAX) dropped from Russell 2500 Growth Benchmark - marketscreener.com
ETFs Investing in Novavax, Inc. Stocks - TradingView
Novavax, Inc.(NasdaqGS: NVAX) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Novavax, Inc.(NasdaqGS: NVAX) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Novavax, Inc.(NasdaqGS: NVAX) dropped from Russell 3000 Growth Benchmark - marketscreener.com
Novavax Q4 Earnings Preview: Wall Street Expects Wider Losses Amid Diversification Efforts - Stocktwits
Price to sales forward of Novavax, Inc. – NASDAQ:NVAX - TradingView
Price to sales forward of Novavax, Inc. – FWB:NVV1 - TradingView
Novavax Swings To Profit In Q4 Fueled By Nuvaxovid-Linked Revenue - Stocktwits
Novavax boosts efficiency and productivity with ServiceNow - NTT Data
NVAX News | NOVAVAX INC (NASDAQ:NVAX) - ChartMill
Enterprise value to EBITDA forward of Novavax, Inc. – NASDAQ:NVAX - TradingView
Enterprise value to EBITDA forward of Novavax, Inc. – SIX:NVAX - TradingView
Novavax Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Enterprise value to revenue forward of Novavax, Inc. – NASDAQ:NVAX - TradingView
Investors heavily search Novavax, Inc. (NVAX): Here is what you need to know - MSN
Enterprise value to revenue forward of Novavax, Inc. – SIX:NVAX - TradingView
Price to sales forward of Novavax, Inc. – SIX:NVAX - TradingView
Enterprise value to EBIT forward of Novavax, Inc. – SIX:NVAX - TradingView
Novavax Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Novavax, Inc. Actuals & Estimates (SIX:NVAX) - TradingView
Price to book forward of Novavax, Inc. – NASDAQ:NVAX - TradingView
These Stocks Are Moving the Most Today: Novavax, Palantir, Shoals, Plug Power, DaVita, and More - Barron's
NVAX Forecast — Price Target — Prediction for 2027 - TradingView
Price to earnings forward of Novavax, Inc. – NASDAQ:NVAX - TradingView
Novavax | 4: Statement of changes in beneficial ownership of securities-Director DOUGLAS RICHARD - Moomoo
Novavax (NVAX) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
Novavax Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Shah Capital campaign falls short at Novavax despite opposition to board, pay - Alternatives Watch
Shah Capital blasts Novavax annual meeting results - The American Bazaar
Novavax faces renewed attack by Shah Capital after AGM - MSN
Novavax Draws Fresh Criticism From Largest Shareholder Shah Capital Following Annual Meeting - citybiz
Novavax (NVAX) Faces Shareholder Backlash Despite AGM Resolutions Approval - GuruFocus
Novavax | 4: Statement of changes in beneficial ownership of securities-Director MOTT DAVID M - Moomoo
Novavax Shareholders Approve Directors, Pay and Incentive Plans - The Globe and Mail
Novavax targeted by Shah Capital after AGM (NVAX:NASDAQ) - Seeking Alpha
Shah Capital Responds to Significant Shareholder Dissent at Novavax AGM - Yahoo Finance
Form 4 Novavax Inc For: 23 June By Investing.com - Investing.com Australia
Novavax (NVAX) director gains RSU and option grants, exercises award - Stock Titan
Novavax Inc Stock (NVAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.18%
2.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):